We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.3M
Cap. Flow
-$3.77M
Cap. Flow %
-6.81%
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$595K
2
AMRN
Amarin Corp
AMRN
+$297K
3
UTHR icon
United Therapeutics
UTHR
+$282K
4
ALKS icon
Alkermes
ALKS
+$253K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$64.5K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$868K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$813K
3
BLUE
bluebird bio
BLUE
+$743K
4
INSM icon
Insmed
INSM
+$690K
5
PCRX icon
Pacira BioSciences
PCRX
+$489K

Sector Composition

Rank Sector Weight
1 Healthcare 54.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$292M
$510K 0.92%
1,682
+850
+102% +$297K
BPMC
27
DELISTED
Blueprint Medicines
BPMC
$498K 0.9%
6,780
– –
BOLD
28
DELISTED
Audentes Therapeutics, Inc
BOLD
$487K 0.88%
17,339
– –
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$475K 0.86%
20,844
– –
GBT
30
DELISTED
Global Blood Therapeutics, Inc.
GBT
$460K 0.83%
9,479
– –
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$453K 0.82%
10,852
– –
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
$447K 0.81%
9,770
– –
ACAD icon
33
Acadia Pharmaceuticals
ACAD
$4.38B
$432K 0.78%
12,005
+24
+0.2% +$728
GWPH
34
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$423K 0.76%
3,674
– –
ZGNX
35
DELISTED
Zogenix, Inc.
ZGNX
$389K 0.7%
9,725
– –
MGNX icon
36
MacroGenics
MGNX
$285M
$384K 0.69%
30,075
– –
NTLA icon
37
Intellia Therapeutics
NTLA
$1.59B
$380K 0.69%
28,490
– –
TECH icon
38
Bio-Techne
TECH
$11.2B
$303K 0.55%
6,204
– –
IQV icon
39
IQVIA
IQV
$34.4B
$297K 0.54%
1,985
– –
AMGN icon
40
Amgen
AMGN
$198B
$294K 0.53%
1,518
+121
+9% +$23.2K
NBIX icon
41
Neurocrine Biosciences
NBIX
$17.2B
$282K 0.51%
3,127
+115
+4% +$10.7K
CKPT
42
DELISTED
Checkpoint Therapeutics
CKPT
$281K 0.51%
11,276
– –
CRL icon
43
Charles River Laboratories
CRL
$10.8B
$280K 0.51%
2,112
– –
UTHR icon
44
United Therapeutics
UTHR
$22.7B
$279K 0.5%
+3,498
New +$282K
GRFS
45
Grifois
GRFS
$4.95B
$264K 0.48%
13,196
– –
BIIB icon
46
Biogen
BIIB
$30.4B
$261K 0.47%
1,123
– –
ICPT
47
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$261K 0.47%
3,926
-1,946
-33% -$131K
GILD icon
48
Gilead Sciences
GILD
$167B
$259K 0.47%
4,082
– –
LGND icon
49
Ligand Pharmaceuticals
LGND
$6.08B
$242K 0.44%
3,892
+508
+15% +$31.9K
NKTR icon
50
Nektar Therapeutics
NKTR
$2.31B
$235K 0.42%
862
+28
+3% +$10.3K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $868K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 56% a quarter earlier.

Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.

  • Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
  • Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
  • Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $131K.
  • Opus Point Partners Management fully exited Immunomedics Inc in Q3 2019, selling an estimated $868K.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
  • Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
  • Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.